Literature DB >> 19244117

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

Jeremy Copp1, Gerard Manning, Tony Hunter.   

Abstract

The mammalian target of rapamycin (mTOR) serine/threonine kinase is the catalytic component of two evolutionarily conserved signaling complexes. mTOR signaling complex 1 (mTORC1) is a key regulator of growth factor and nutrient signaling. S6 kinase is the best-characterized downstream effector of mTORC1. mTOR signaling complex 2 (mTORC2) has a role in regulating the actin cytoskeleton and activating Akt through S473 phosphorylation. Herein, we show that mTOR is phosphorylated differentially when associated with mTORC1 and mTORC2 and that intact complexes are required for these mTORC-specific mTOR phosphorylations. Specifically, we find that mTORC1 contains mTOR phosphorylated predominantly on S2448, whereas mTORC2 contains mTOR phosphorylated predominantly on S2481. Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive. Thus, phospho-S2481 on mTOR serves as a biomarker for intact mTORC2 and its sensitivity to rapamycin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244117      PMCID: PMC2652681          DOI: 10.1158/0008-5472.CAN-08-3014

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Robert R Latek; Kalyani V P Guntur; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

2.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

3.  FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions.

Authors:  R T Peterson; P A Beal; M J Comb; S L Schreiber
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

4.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Authors:  A Sekulić; C C Hudson; J L Homme; P Yin; D M Otterness; L M Karnitz; R T Abraham
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

5.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

6.  PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival.

Authors:  Lana Bozulic; Banu Surucu; Debby Hynx; Brian A Hemmings
Journal:  Mol Cell       Date:  2008-04-25       Impact factor: 17.970

7.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

8.  Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status.

Authors:  Susan W Y Cheng; Lee G D Fryer; David Carling; Peter R Shepherd
Journal:  J Biol Chem       Date:  2004-02-17       Impact factor: 5.157

9.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2.

Authors:  Laura R Pearce; Xu Huang; Jérôme Boudeau; Rafał Pawłowski; Stephan Wullschleger; Maria Deak; Adel F M Ibrahim; Robert Gourlay; Mark A Magnuson; Dario R Alessi
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

10.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.

Authors:  Laura S Harrington; Greg M Findlay; Alex Gray; Tatiana Tolkacheva; Simon Wigfield; Heike Rebholz; Jill Barnett; Nick R Leslie; Susan Cheng; Peter R Shepherd; Ivan Gout; C Peter Downes; Richard F Lamb
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  206 in total

Review 1.  Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Authors:  Qi-Wen Fan; William A Weiss
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Human cytomegalovirus induces multiple means to combat reactive oxygen species.

Authors:  Carisa Tilton; Amy J Clippinger; Tobi Maguire; James C Alwine
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.

Authors:  Nicole D Facompre; Indu Sinha; Karam El-Bayoumy; John T Pinto; Raghu Sinha
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

4.  Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.

Authors:  Delphine Boulbes; Chien-Hung Chen; Tattym Shaikenov; Nitin K Agarwal; Timothy R Peterson; Terri A Addona; Hasmik Keshishian; Steven A Carr; Mark A Magnuson; David M Sabatini; Dos D Sarbassov
Journal:  Mol Cancer Res       Date:  2010-05-25       Impact factor: 5.852

5.  Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.

Authors:  Barbara Kroczynska; Sonali Joshi; Elizabeth A Eklund; Amit Verma; Sergei V Kotenko; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

6.  Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Authors:  Barbara Kroczynska; Robert L Rafidi; Beata Majchrzak-Kita; Ewa M Kosciuczuk; Gavin T Blyth; Jacek Jemielity; Zofia Warminska; Diana Saleiro; Swarna Mehrotra; Ahmet Dirim Arslan; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2015-12-08       Impact factor: 5.157

7.  Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation.

Authors:  Shirish Paranjpe; William C Bowen; Wendy M Mars; Anne Orr; Meagan M Haynes; Marie C DeFrances; Silvia Liu; George C Tseng; Anastasia Tsagianni; George K Michalopoulos
Journal:  Hepatology       Date:  2016-10-01       Impact factor: 17.425

8.  Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Authors:  Husheng Ding; Jennifer S McDonald; Seongseok Yun; Paula A Schneider; Kevin L Peterson; Karen S Flatten; David A Loegering; Ann L Oberg; Shaun M Riska; Shengbing Huang; Frank A Sinicrope; Alex A Adjei; Judith E Karp; X Wei Meng; Scott H Kaufmann
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

9.  Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1

Authors:  Stephanie N Hurwitz; Mujeeb R Cheerathodi; Dingani Nkosi; Sara B York; David G Meckes
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

10.  Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.

Authors:  Alejandro Vazquez-Martin; Tamara Sauri-Nadal; Octavio J Menendez; Cristina Oliveras-Ferraros; Sílvia Cufí; Bruna Corominas-Faja; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.